Treatment options are needed for patients that do
The concentrations of ketoconazole that inhibited human chorionic gonadotropin stimulation of testicular androgen production and displaced sex steroids
The introduction of androgen deprivation therapies into the treatment paradigm for prostate cancer patients has resulted in a wide variety of benefits ranging
The term “castration-resistance” has evolved after initial observations that the use of conventional secondary hormonal therapies such as ketoconazole, alternative anti-androgens, aminoglutethimide, provided continued clinical response despite initial progression on androgen deprivation therapy
Ketoconazole blocks the synthesis of ergosterol, a key component of the fungal cell membrane, through the inhibition of cytochrome P-450 dependent enzyme lanosterol Testosterone levels are impaired with doses of 800 mg per day and abolished by 1600 mg per day
2
Ketoconazole, an imidazole antifungal agent with inhibitory activity of the cytochrome P450 17A1 complex (CYP17), has demonstrated clinical activity in patients with metastatic castration-resistant prostate cancer (mCRPC) in prospective clinical trials (1, 2) and has been used for decades in the treatment of this disease ()
Ketoconazole is a new, orally effective, antifungal agent
Spironolactone
On the other hand, ketoconazole showed a significant decrease in the MICs and MBCs of the tested antibiotics against S
Could a topical anti-androgen be effective in treating AV? Dermatologists have been using topical ketoconazole for years treating seborrheic dermatitis, psoriasis, and dermatophytosis
Another mechanism that may influence the pathogenesis of CRPC involves the effect of ketoconazole on T cell 2
Anti-androgens
Androgen-receptor antagonists such as flutamide and bicalutamide can be used in combination with a gonadotropin-releasing hormone (GnRH) analog in the treatment of metastatic prostate cancer
found that AKR1C3 expression was